Back to Search
Start Over
Usability of the SB11 Pre-filled Syringe (PFS) in Patients with Retinal Diseases.
- Source :
- Advances in Therapy; Aug2024, Vol. 41 Issue 8, p3426-3436, 11p
- Publication Year :
- 2024
-
Abstract
- Introduction: SB11 (Byooviz™; Samsung Bioepis Co., Ltd.) is a ranibizumab (Lucentis<superscript>®</superscript>; Genentech, Inc.) biosimilar targeting vascular endothelial growth factor A for the treatment of retinal diseases. The pre-filled syringe (PFS) presentation of SB11 offers an alternative administration method to the vial, with the potential for enhanced safety and efficient syringe preparation. The objective of this study was to assess the ability of healthcare professionals (HCPs) to follow the instructions for use to prepare and administer SB11 PFS intravitreal (IVT) injections to patients with neovascular age-related macular degeneration (nAMD) or macular edema secondary to retinal vein occlusion (RVO). Methods: This study was an open-label, single-arm, single-dose clinical study to evaluate the usability of the SB11 PFS in patients with nAMD or macular edema secondary to RVO. Four HCPs prepared and administered 0.5 mg SB11 PFS IVT injections to 34 patients. Product use task completion (12 tasks in total) was assessed by independent observers. Safety was assessed up to 7 days after injection of the investigational product. Results: A total of 34 patients were enrolled and completed the study. All 12 tasks were successfully completed in 34 (100%) patients without a use-related failure. Most patients (32 patients, 94.1%) experienced no adverse events (AEs), whereas 2 (5.9%) patients experienced three treatment-emergent AEs (TEAEs) which were mild to moderate in severity. There were no severe or serious TEAEs reported during the study. Conclusions: This study showed that HCPs were able to successfully prepare and administer the SB11 PFS via IVT injection. No unexpected safety issues were identified. The SB11 PFS is a promising alternative for therapeutic administration of SB11 in patients with retinal disease. Trial Registration: ClinicalTrials.gov identifier NCT06176963; EudraCT number 2021-003566-12. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0741238X
- Volume :
- 41
- Issue :
- 8
- Database :
- Complementary Index
- Journal :
- Advances in Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 178560029
- Full Text :
- https://doi.org/10.1007/s12325-024-02937-3